Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 Years and Older With and Without Atopic Comorbidities. J of Skin 2024, 8 (1), s322. https://doi.org/10.25251/skin.8.supp.322.